Page 21234..1020..»

Category : Human Longevity

Asymmetrex Publishes the First Report of Immortal DNA Strands in Human Stem Cells – PR Web

Example of a tissue stem cell (left) holding on to its immortal DNA strands after dividing to produce a maturing tissue cell (right).

BOSTON (PRWEB) November 18, 2020

What does it mean for multiplying cells in the body to be immortal? The cell DNA is being replicated over and over again while being divided equally between new cells produced by cell divisions. All the new cell components produced by the DNA code are mixing with the old cell components and being divided between the new cells. So, every cell is a new cell. There is nothing really immortal about any of them. Right?

Not quite. Stem cells responsible for renewing other mature body cells are different. For a long time, tissue cell scientists had a somewhat nebulous idea that stem cells had a special longevity in organs and tissues that they were immortal cells, lasting for as long as the human lifespan. However, no one had a molecular concept for this idea of stem cell immortality until John Cairns, a pioneer of DNA replication, started thinking about DNA mutations and cancer in the 1970s.

Cairns predicted that stem cells did something unique with their DNA code. He said they held on to one strand of every one of their many chromosomes and never shared those DNA strands with the tissue cells they renewed. Cairns called these immortal DNA strands. Cairns argued that immortal DNA strands must exist to explain how immortal stem cells avoid higher cancer rates.

Asymmetrex director James Sherley calls the immortal strand hypothesis the Carpenters Rule for stem cells. Good carpenters avoid creeping measurement errors by using a ruler or the same piece of wood to measure duplicates. Too many DNA duplication errors in cells make them cancerous. Cairns proposed that stem cells were smart carpenters, keeping and using the same DNA strands for making their many replicate copies over the human lifespan.

Prior to Asymmetrexs new report, published in a special issue of the peer-reviewed journal Symmetry, there were many publications on the presence of immortal DNA strands in stem cells of other species, including molds, plants, insects, and mice. Low levels of immortal DNA strands were also reported for human cancer cells.

The new report from Asymmetrex describes the presence of immortal DNA strands in human liver stem cells. The SACK-Xs 12(3) stem cells used in the study were developed more than a decade earlier using Asymmetrexs patented SACK tissue stem cell expansion technology. SACK-Xs 12(3) human liver stem cells are distributed for research by Kerafast. They are the first and only commercial human tissue stem cell product supplied with their stem cell-specific dosage, certified by Asymmetrex.

The new report brings an important closure for an ingenious scientific deduction by a remarkable scientist, John Cairns, recently deceased. Now that normal human tissue stem cells are confirmed to have immortal DNA strands, scientists can get on with the business of leveraging this knowledge to a better understanding of tissue stem cells for improving human health.

About Asymmetrex

Asymmetrex, LLC is a Massachusetts life sciences company with a focus on developing technologies to advance stem cell medicine. The companys U.S. and U.K. patent portfolio contains biotechnologies that solve the two main technical problems production and quantification that have stood in the way of effective use of human adult tissue stem cells for regenerative medicine and drug development. Asymmetrex markets the first technology for determination of the dose and quality of tissue stem cell preparations for use in stem cell transplantation therapies and pre-clinical drug evaluations. Asymmetrex is a member company of the Advanced Regenerative Manufacturing Institute BioFabUSA and the Massachusetts Biotechnology Council.

Share article on social media or email:

Read more:
Asymmetrex Publishes the First Report of Immortal DNA Strands in Human Stem Cells - PR Web

Recommendation and review posted by Alexandra Lee Anderson

Korea plans up to W10tr investment for biohealth by 2023 – The Korea Herald

President Moon Jae-in expresses appreciation for Samsung Biologics` 1.7 trillion won and Celltrion`s 500 billion won investments in biologics industry, promises 1.7 trillion won national budget for biohealth industry in 2021, at a memorandum of understanding ceremony held at Yonsei University Global Campus in Songdo, Incehon, on Wednesday. (Yonhap)

Samsung Biologics will pour 1.7 trillion won ($1.54 billion) into its new Plant 4, and Celltrion 500 billion won to its Global Life Science Research Lab and Plant 3. The Government also pledged 1.7 trillion won budget in 2021 for bio health industry, which is a 30 percent increased budget compared to last years, reflecting the growing interest from the Korean government to build up the national ecosystem for biologics industry. By 2023, the total amount of private investments for biohealth industry will amount to 10 trillion won, the Korean government projected.

President Moon Jae-in personally attended the memorandum of understanding ceremony Wednesday at Yonsei University Global Campus in Songdo to encourage and promise governmental support in the private companies endeavors.

Also among the attendees were Finance Minister Hong Nam-ki, who doubles as deputy prime minister for economic affairs, Industry Minister Sung Yoon-mo, Science Minister Choi Ki-young, Health Minister Park Neung-hoo and Drugs Minister Kim Gang-lib, as well as Incheon Mayor Park Nam-choon. Heads of parts and equipment companies Junghyun Plant and Wiatek and students in biologics and relevant fields were also included.

Koreas action plan for a more robust bio industry ecosystem is to inject 1.7 trillion won from the budget in 2021, up 30 percent from that assigned a year prior, and to foster specialized future experts and collaboration with small and medium-sized companies.

In the world market, the biologics industry is notching an annual average growth rate of 4 percent, higher than makers of ships at 2.9 percent and automakers at 1.5 percent, according to the government agencies.

Taking this into consideration, the biohealth players in Korea are seeking to create synergy by building an ecosystem for biologics in Songdo.

There are now over 60 bio-related companies in Songdo, including both Korean and global firms. These firms employ some 7,000 workers.

By 2023, about 10 trillion won of investment is expected to be made in the city by some 40 health care and venture capital firms, resulting in an annual 20 percent growth of manufacturing capacity and the additional employment of approximately 9,300.

The government envisions growing a workforce of some 47,000 in biologics by 2025 in a joint effort with the industry and academia. To that end, at Yonsei University Global Campus a center to foster biologics processing experts will be established.

In the big picture of nationwide efforts to grow the biologics industry, regional bio clusters of Songdo in Incheon, Wonju in Gangwon Province, Osong in North Chungcheong Province and Daegu will increase collaboration.

The governmental budget of 1.7 trillion won will prioritize pharmaceuticals, medical devices and digital health care, in that order.

Samsung Biologics groundbreaking ceremony for Plant 4 takes place Wednesday in Songdo, Incheon. (Samsung Biologics)

Projected to begin partial manufacturing from 2022 and full operations in 2023, Plant 4 will have capacity of 256,000 liters. This surpasses the record of Samsung Biologics Plant 3 as the largest biologics manufacturing plant in the world with 180,000 liters.

The Super Plant alone will sprawl across 238,000 square meters, nearing the combined land size of Samsung Biologics Plants 1, 2 and 3 combined, at 240,000 square meters.

The company will inject 1.74 trillion won to build the massive plant, and employ an additional workforce of 1,850.

Once Plant 4 is complete, Samsung Biologics will purchase another slab of land in Songdo to start a second campus of its facilities, Samsung Biologics CEO Kim Tae-han said at the ceremony.

Celltrions proposed Global Life Science Research Center (Celltrion)

The antibody maker is not stopping there -- Celltrion Chairman Seo Jung-jin said at Wednesdays event that the company is mulling Plant 4 in the near future, with aims to expand its total production output to 600,000 liters as fast as the company can manage.

If executed, this plan would triple Celltrions current manufacturing capacity of 190,000 liters in a single generation. According to Seo, Celltrion is mulling facilities of 200,000 liters in Songdo, with the rest located overseas.

Global Life Science Research Center will complete construction by July 2022 and accommodate 2,500 additional researchers. Plant 3 will have its groundbreaking in 2021 and finish building by May 2023.

How we compete against multinational companies with more than a century of history is through advanced technology and our fighter spirit, Seo said.

Celltrion will carry out in stages investments of 40 trillion won through 2030.

Celltrion began in 2002 as a six-person startup. This year, it is on track to place No. 30-35 among some 300,000 biologics companies in terms of operating profit.

With Samsung Biologics and Celltrions investments, Korea as a nation will have the capacity to manufacture 910,000 liters of biologics a year. Songdo as a city will have the worlds biggest manufacturing output of biologics substances.

The reason we must combine forces in the bio industry is clear, because it is something we can be good at, said President Moon Jae-in at the ceremony.

The answer to humanitys wishes to live long healthily lies in the bio industry, Moon said. And so long as human longevity continues to lengthen, the bio industry will always be a future growth driver.

Just a few years ago, biologics was an area with a great hurdle. When the free trade agreement between the US and Korea was signed, we expected bio to suffer among the worst blows, Moon said.

But now the Republic of Korea is rewriting history for the bio industry. For now, we only account for 2 percent of the world bio market. But armed with global No. 2 capability to manufacture biopharmaceuticals, we now have the growing confidence that we can achieve greater goals, Moon said.

Heading forward, Koreas Industry, Science and Health ministries would work to combine electronics, chemicals, energy, manufacturing, data, networks, artificial intelligence and semiconductors with biotechnologies.

This is anticipated to bring forth innovative research on human-augmented robots, cerebral computer interfaces, eco-friendly plastics, functional fibers, renewable green energy and breakthroughs in manufacturing models leveraging microorganisms.

Big data with biotech will enable customized personal treatments, while communications will enable real-time patient monitoring. Artificial intelligence will help conduct research more quickly, with semiconductors and software technologies aiding in early diagnoses.

By Lim Jeong-yeo (

Read more:
Korea plans up to W10tr investment for biohealth by 2023 - The Korea Herald

Recommendation and review posted by Alexandra Lee Anderson

20 Years of Observing Earth From the Space Station An Extraordinary View From Outer Space – SciTechDaily

The International Space Station has been continuously occupied for two decades, and the astronauts and cosmonauts aboard have taken more than 3.5 million photographs of our home planet from space. Credit: NASA

After 20 years of continuous human presence, the International Space Station (ISS) has provided 241 visitors with an extraordinary view of Earth from outer space one they have shared with the rest of the world.

Astronaut photography, formally called Crew Earth Observations (CEO), has resulted in more than 3.5 million photographs of the ever-changing blue planet. But camera-wielding astronauts are not the only ones looking down at Earth from their perch in the sky. An impressive suite of Earth Science instruments have also visited the station to capture vast amounts of data about our planet.

However, space aboard the station itself is limited, and the spots are highly coveted. Instruments go through a rigorous approval process and cycle through every couple of years, turning the station into a virtual swiss-army knife of interchangeable remote sensing tools. An especially comprehensive suite of Earth observing instruments are currently aboard the station, with two more approved and several more proposing to become future ISS instruments.

These instruments complement one another to provide a more complete picture of Earth systems, according to William Stefanov, branch chief for the Exploration Science Office at NASAs Johnson Space Center, and principal investigator for the Crew Earth Observations Facility on the International Space Station. Thats why its serendipitously great that all of these instruments are on the International Space Station and functioning simultaneously, Stefanov said.

The ECOsystem Spaceborne Thermal Radiometer Experiment on Space Station (ECOSTRESS) is located on the Japanese Experiment Module on the International Space Station. Credit: NASA


The human crew came in especially handy for the Ecosystem Spaceborne Thermal Radiometer Experiment on Space Station (ECOSTRESS) instrument, which records the temperature of plants on Earths surface by measuring the heat they give off. The instrument required the addition of Wi-Fi modules to transmit its data to the station, which in turn required astronauts to conduct a spacewalk to install them.

Since then, ECOSTRESS has provided new insights into the relationship between plant temperatures and water usage. It can identify plant stress down to an individual farmers field, when intervention and water management may still be possible to save crops.

Principal investigator Simon Hook says scientists have only just begun to scratch the surface of how the instrument can be used based on its frequent and high-resolution temperature measurements. There is work underway to use the temperature data to observe wildfires, droughts, volcanoes, and heat waves, or even to identify heat patterns within urban cities.


From fields to forests, another plant-focused instrument is the Global Ecosystem Dynamics Investigation(GEDI). Using lidara method of bouncing a laser off the planet and measuring how long it takes the signal to returnGEDI is creating a record of the three-dimensional structure worlds tropical and temperate forests so that Earths tree canopies can be mapped and tracked over time.

The vertical structure of forests, which is essentially the height of the trees and how their leaves and branches are arranged vertically, can help determine how much carbon storage is lost from deforestation or gained from growing forests. GEDI principal investigator Ralph Dubayah, professor of Geographical Sciences at the University of Maryland, College Park, says this is the biggest uncertainty we have about the global carbon cycle, and why there is so much attention put on understanding how deforestation and tree growth contribute to atmospheric carbon dioxide concentrations. GEDI is a collaborative effort between NASA and UMD.

Measurements from the Global Ecosystem Dynamics Investigation (GEDI) show that tree canopy peaks in the middle of the African continent what we know as the Congo Basin. Credit: University of Maryland

To supply its high-power laser, GEDI takes advantage of the massive solar panels on the station. Right now on the International Space Station we have an amazing confluence of instruments that together are able to observe ecosystem function, structure and plant composition, Dubayah said. And it was entirely made possible because we have this incredible science platform in the ISS.


Being high above the clouds also makes the station a good platform for observing the weather. NASAs Lightning Imaging Sensor (LIS) records the time, energy output and locations of lightning events around the world in the lower atmosphere. It can provide information on when storms are growing or decaying, thereby helping to improve weather forecasting models and aircraft/spacecraft safety precautions.

It complements the Geostationary Lightning Mapper (GLM) aboard the Geostationary Operational Environmental Satellite (GOES-16), which is a collaboration between NASA, the National Atmospheric and Oceanic Administration (NOAA) and industry partners, and the European Space Agencys (ESA) monitoring of thunderstorms and upper atmosphere lightning events through the Atmosphere Space Interaction Monitor (ASIM) instrument which is on the ISS.

The data from ASIM and LIS are both able to capture the impacts of dust storms, pollution, fires, and volcanic eruptions on cloud formation and electrification. This is just one example of how ESA, and other international agencies including the German Aerospace Center(DLR) andthe Japan Aerospace Exploration Agency (JAXA), are also helping advance a global understanding of our planet through ISS-instruments with Earth observations of their own.


Several instruments currently aboard the station are not the first of their kind. As the name might suggest, the Orbiting Carbon Observatory-3(OCO-3) is a third iteration instrument for long-term monitoring of atmospheric carbon dioxide distributions around the globe, complementing long-term ground-based observations. It provides insights into regional carbon sources and sinks and monitors changes in the carbon cycle linked to human activity.

Together with GEDI and ECOSTRESS, OCO-3 contributes to a more complete picture of terrestrial ecosystems. While its predecessor, the OCO-2 satellite, followed a polar orbit, OCO-3s path aboard the station offers a denser data set for areas with large carbon fluxes, including Earths most biologically diverse regions like the Amazon rainforest.

The orbit also allows measurements at different times of day, which especially benefits ECOSTRESS and OCO-3 as plants and their contribution to the carbon cycle fluctuate with time of day due to variations in sun, temperature and water availability.


Like OCO-3, the Stratospheric Aerosol and Gas Experiment (SAGE) III, is a third-generation instrument. The successive SAGE instruments have provided an ongoing record of Earths upper atmospheric water vapor, aerosol and ozone which make up the protective sunscreen layer for the planet.

The stratospheric aerosol and gas experiment (SAGE) IIIs line of sight from the international space station provides a view of the aerosols and gases present in Earths atmosphere by taking advantage of the sunlight traveling through a slice of the atmosphere. Credit: NASA

When sunlight passes through the upper atmosphere, its unique mixture of particulates and gases create the picturesque colors of spectacular sunsets and sunrises. To replicate a sunset or sunrise view from the space station, SAGE III looks at Earth from a side angle, capturing a similar view of the atmosphere on its edge as someone watching the sunset from the ground. But from its vantage point of space, SAGE III can view the entirety of these atmospheric layers according to project scientist Dave Flittner, and sees 15 sunrises and sunsets every day.

Science manager Marilee Roell says the longevity of these observations has been crucial to monitoring and maintaining the protective ozone layer in the upper atmosphere. SAGE II closely monitored the past ozone decline from common aerosols in hair sprays and fire retardants that degraded the layer, and its data informed the Montreal Protocol Treaty, which phased out the use of these damaging chemicals.

Its one of the biggest success stories of science informing policy, said Roell. And not only is this a premier science instrument, but its also on the International Space Stationa crewed platform. We are kind of getting the best of both science and getting to be a part of the human spaceflight program in a peripheral way.


Additional atmospheric measurements of the sun come from the Total and Spectral Solar Irradiance Sensor(TSIS-1) which is actually made of two instruments: the Total Irradiance Monitor (TIM) and Spectral Irradiance Monitor (SIM).

TSIS-1 continues the work of NASAs Solar Radiation and Climate Experiment satellitebymeasuring the amount of sunlight that reaches Earth, and how it is distributed in wavelength.

These measurements of solar energy, along with model-based calculations of its absorption and reflection by Earths atmosphere and surface, provide insights into the suns influence on climate, the ozone layer, atmospheric circulation, and ecosystems. The data are critical inputs for modeling of Earths climate and atmospheric systems.


There is still more to learn about Earth, and new instruments which can further contribute to our understanding like the Climate Absolute Radiance and Refractivity Observatory (CLARREO) Pathfinder and the Earth Surface Mineral Dust Source Investigation (EMIT) are already scheduled to reach the station within the next couple of years.

The CLARREO Pathfinder will measure sunlight reflected off Earth, and take direct measurements of the Sun, with unparalleled accuracy. The data can then help calibrate other sensors starting in 2021. EMIT is scheduled to launch the following year in 2022 to map dust-source regions on Earths surface and assess the impact of dust on the warming and cooling of the atmosphere.

Its been really satisfying to see the range of things we have had on the space station, said Stefanov. From imaging systems to lasers and radars, and more recently hyperspectral instruments Stefanov believes that the limit to what they can do in the future is really only limited by what scientists and engineers are able to design and the number of instrument ports available.

There will be opportunities for new sensors to go up to the station, he said. And I think it will continue to develop as a very useful remote sensing platform for Earth observations going forward.

See more here:
20 Years of Observing Earth From the Space Station An Extraordinary View From Outer Space - SciTechDaily

Recommendation and review posted by Alexandra Lee Anderson

Global AI Medicine Software Market Analysis of Key Players, Type, Application, Demand and Consumption By 2026 – Stock Market Vista

There are millions of them around the globe waiting for clutching on to some of the latest vital information circulating across the globe. The up-to-the-minute AI Medicine Software market report based on the growth and the development of theAI Medicine Software marketis systematically listed down. The AI Medicine Software market report comprises statistically verified facts such the unique essence including topological investigations, worldwide market share, government stringent norms, applications, current trends, futuristic plans, market bifurcations, and so on mentioned in a crystal clear pattern.

The statistical plus scientific AI Medicine Software market report has all the important market aspects penciled down in a layman language format so that the data based on the markets productivity or future strategy can be easily extrapolated from the reports. The AI Medicine Software market report has the dominant market players Tempus Labs, Inc., Flatiron Health, Inc., Gene42, Inc., Sunquest Information Systems Inc, 2bPrecise LLC, NantHealth, Inc, IBM Watson Group, Human Longevity, Inc., N-of-One, Inc., Translational Software, Inc, SOPHiA GENETICS SA, Syapse, Inc., LifeOmic Heal explained in detail.

Sample of global AI Medicine Software Market Report at::

The essential futuristic segments such as {Machine Learning, Natural Language Processing, Others}; {Drug Discovery, Precision Medicine, Others} have also been detailed out in the AI Medicine Software market report for the clients convenience and more of vital data embracing capability. The forecast trends along with the current market status can better understand the AI Medicine Software market development on a global basis. The intricate industrial strategies and the supply-demand chain are also discussed in the contextual report.

Key points of the global AI Medicine Software market

Theoretical analysis of the global AI Medicine Software market stimulators, products, and other vital facets Recent, historical, and future trends in terms of revenue and market dynamics are reported Pin-point analysis of the competitive market dynamics and investment structure is predicted to grow Future market trends, latest innovations, and various business strategies are reported Market dynamics include growth influencers, opportunities, threats, challenges, and other crucial facets

The AI Medicine Software market report has the imperative data mentioned in a systematic way only after comprehensive inspection and vigilant referencing. The diagrammatic representations such as a pie chart of the AI Medicine Software market are also drawn out so as to attract the punters and make it easy for them to comprehend the entire AI Medicine Software market from in and out. The most eye-catching format of the AI Medicine Software market report is its market bifurcation based on the product type, application, geography, end-users, and more as per the particular market. The geographical segments Europe, North America, Latin America, Asia Pacific, and Middle East & Africa are further exhaustively mentioned.

Read Detailed Index of full Research Study at::

Questions answered in the report include

1. What is the expected market size by the end of the forecast period?2. What are the major factors initiating the global AI Medicine Software market growth?3. What are the latest developments and trending market strategies that are influencing the growth of the AI Medicine Software market?4. What are the key outcomes of the AI Medicine Software market developments?5. Who are the key players in the market?6. What are the opportunities and challenges faced by the key players?

The AI Medicine Software market report endows the global market dominance, market segmentation, growth factors, and others reported such that the clients can have a total tour of the market without any much off efforts needed.

Key Reasons for Purchasing Global AI Medicine Software Market Report

New approaches and latest development trend that describe the structure of the market Advanced market breakdown structure Historical data and future market scope In-depth market analysis based on statistics, growth stimulators, and market developments Statistical data representation through figurative, numerical, and theoretical elaboration Report provides insight of the business and sales activities

Ask Any Kind of Query Before Purchasing the Report Here:

Originally posted here:
Global AI Medicine Software Market Analysis of Key Players, Type, Application, Demand and Consumption By 2026 - Stock Market Vista

Recommendation and review posted by Alexandra Lee Anderson

4 Reasons To Use Cannabis For Treating Women’s Health Issues – Longevity LIVE

Specific dietary changes, like including natural supplements, can help in enhancing sexual energy in women. Aphrodisiacs are the foods, drinks, or drugs that help increase female libido. Cannabis is another such natural aphrodisiac that can help increase womens libido. Cannabis can also help in reducing the pain during penetration experienced by some women.

According to a study, women who ate cannabis experienced two times higher sex drives, with satisfactory orgasms than those with irregular cannabis usage. Cannabis interacts with endocannabinoids in the body, which help regulate sexual function. Women can use cannabis as an aphrodisiac in many ways. Earlier, people used to take it in the form of a beverage, but today, there are many different consumption methods. Women can also use cannabis as lubricants, helping in reducing pain during sex.

Mental health disorders affect both men and women, but theyre more severe in women. Various factors like career, family responsibility, and abuse are significant causes of mental issues in women. The most common mental illness in women is depression, bipolar disorder, and schizophrenia, often challenging to diagnose.

According to an article, cannabis has antidepressant traits that help decrease anxiety and depression in women. The depletion of serotonin in the brain leads to depression. However, taking cannabis in low doses helps release serotonin, which causes anti-depressant effects. This can help in alleviating stress and anxiety, as well as assisting in doing day-to-day activities.

These are some of the benefits of cannabis for women. Research states that one should always use cannabis from low doses to reap the right health benefits. Buy cannabis products from reputed shops that will provide authentic cannabis products. Make sure to check the THC and CBD content in the product to understand the dosage. You may need to think twice if you have any medical condition or are taking any medication. If you fall into either of these groups, make sure to consult a health professional before starting cannabis.

Denson, T. F., & Earleywine, M. (2006). Decreased depression in marijuana users.Addictive behaviors,31(4), 738742.

Lynn, B. K., Lpez, J. D., Miller, C., Thompson, J., & Campian, E. C. (2019). The Relationship between Marijuana Use Prior to Sex and Sexual Function in Women.Sexual medicine,7(2), 192197.

Olh, A., Tth, B. I., Borbr, I., Sugawara, K., et al. (2014). Cannabidiol exerts sebostatic and antiinflammatory effects on human sebocytes. The Journal of clinical investigation,124(9), 37133724.

Read more:
4 Reasons To Use Cannabis For Treating Women's Health Issues - Longevity LIVE

Recommendation and review posted by Alexandra Lee Anderson

Global Adrenomyeloneuropathy Treatment Market Size, Share, Trends, CAGR by Technology, Key Players, Regions, Cost, Revenue and Forecast 2020 to 2025 -…

New Market Research Report: on Adrenomyeloneuropathy Treatment Market size | Segment by Applications (Hospitals, Clinics, Ambulatory Surgical Centers and Others), by Type (Steroid Replacement Therapy and Stem Cell Transplant), Regional Outlook Opportunity, Market Demand, Latest Trends, Adrenomyeloneuropathy Treatment Industry Share & Revenue by Manufacturers, Leading Companies Profiles, Analysis, Growth Forecast 2025. Analyzes current market size and upcoming Few years' growths of this industry.

Adrenomyeloneuropathy Treatment Market Size report is the best source that gives CAGR values with variations during the forecast period of 2020-2025 for the market. The study encompasses market drivers and restraints by using SWOT analysis, along with their impact on the demand over the forecast period. This global market report endows with a profound overview of product specification, product type, production analysis, and technology by taking into consideration the major factors such as revenue, cost, and gross margin. The Adrenomyeloneuropathy Treatment advertising report has been prepared based on the market type, size of the organization, availability on-premises, and the end-users organization type.

Some of the prominent players operating in the global Adrenomyeloneuropathy Treatment market include Ascend Biopharmaceuticals, Immatics Biotechnologies, Human Longevity, Novadip Biosciences, BioRestorative Therapies, Eureka Therapeutics, Cytori Therapeutics, Allogene Therapeutics, Regeneus, NewLink Genetics and Talaris Therapeutics among others.

Request Sample Copy of this Report @

Competitive Analysis: Adrenomyeloneuropathy Treatment Market

Global Adrenomyeloneuropathy Treatment market Size is highly fragmented and the major players have used various strategies such as new product launches, expansions, agreements, joint ventures, partnerships, acquisitions, and others to increase their footprints in this market. The report includes market shares of Adrenomyeloneuropathy Treatment market Share for global, Europe, North America, Asia-Pacific, South America, and Middle East & Africa.

Global Adrenomyeloneuropathy Treatment Market Split by Product Type and Applications:

Based on Types:

Based on Application:

The latest research on the Adrenomyeloneuropathy Treatment Market Size fundamentally delivers insights that can empower stakeholders, business owners, and field marketing executives to make effective investment decisions driven by facts and extremely thorough research. The study aims to provide an evaluation and deliver essential information on the competitive landscape to meet the unique requirements of the companies and individuals operating in the Adrenomyeloneuropathy Treatment Market for the forecast period, 20202025. To help firms comprehend the Adrenomyeloneuropathy Treatment industry in multiple ways, the report exhaustively assesses the share, size, and growth rate of the business worldwide.

Report Highlights:

The report covers the shifting industry dynamics

Detailed information about the market segmentation

Covers past, present and projected industry size Recent industry trends

Key Competition landscape

Business strategies of key players and product offerings

Potential and niche segments/regions exhibiting promising growth

A neutral perspective towards market performance

Queries Resolved In This Report:

Which will be the specialties at which Adrenomyeloneuropathy Treatment Market players profiling with intensive designs, financials, and ongoing headways should set nearness?

Which will be the foreseen development rates for your own Adrenomyeloneuropathy Treatment economy out and out and each portion inside?

Which will be the Adrenomyeloneuropathy Treatment application and sorts and estimate joined intently by makers?

Which will be the dangers which will attack growth?

The length of the global Adrenomyeloneuropathy Treatment market opportunity?

How Adrenomyeloneuropathy Treatment Market share advance vacillations of their value from various assembling brands?

Chapters Define in TOC (Table of Content) of the Report:

Chapter 1: Market Survey, Drivers, Restraints and Good fortune, Segmentation overview

Chapter 2: Market competitiveness by Manufacturers

Chapter 3: Production by Regions

Chapter 4: Consumption by Regions

Chapter 5: Production, By Types, Revenue and Market share by Types

Chapter 6: Consumption, By Applications, Market share (%) and Growth Rate by Applications

Chapter 7: Overall profiling and analysis of Manufacturers

Chapter 8: Manufacturing cost analysis, Raw materials analysis, Region-wise manufacturing expenses

Chapter 9: Supply Chain, Sourcing Strategy and Downstream Buyers

Chapter 10: Marketing Strategy Analysis, Distributors/Traders

Chapter 11: Market Influence Factors Analysis

Chapter 12: Market Predict

Chapter 13: Adrenomyeloneuropathy Treatment Research Findings and Conclusion, Appendix, methodology and data source

Request Customization on This Report @

Continue reading here:
Global Adrenomyeloneuropathy Treatment Market Size, Share, Trends, CAGR by Technology, Key Players, Regions, Cost, Revenue and Forecast 2020 to 2025 -...

Recommendation and review posted by Alexandra Lee Anderson

US listing set to support and accelerate ongoing development of 4D Pharma’s live biotherapeutics –

The move follows the merger it announced late last month with the NASDAQ listed, Longevity, a special purpose acquisition company (SPAC). 4D Pharma will become dual-listed and ordinary shares will continue to be traded on AIM.

Live biotherapeutics, a novel class of drug derived from the microbiome,are defined by the US Food and Drug Administration (FDA) as being biological products that contain a live organism, such as a bacterium, that is applicable to the prevention, treatment or cure of a disease.

The merger is set to be completed and effective in early 2021, said the UK firm. But it is subject to approval by 4D Pharma and Longevity shareholders and it is also bound by the SEC review process.

The US listing is set to support and accelerate ongoing development of its live biotherapeutics, said the CEO, Duncan Peyton.

It is a big step for 4D Pharma, it is a big step for any European biotech business to step across the Atlantic and become a US listed business. It is something we have worked on for a while, he told BioPharma-Reporter.

The benefits are evident, he said. We get access to strong healthcare funds that understand innovative technologies like live biotherapeutics, we get access to more capital."

4D Pharma, which was officially founded in 2014, is at a pivotal time in its growth and development, said the CEO.

4D Pharma's live biotherapeutic products (LBPs) are orally delivered single strains of bacteria that are naturally found in the healthy human gut, and it has developed a proprietary platform, MicroRx (R), that identifies live biotherapeutics based on a deep understanding of function and mechanism.

Its clinical programs target cancer, including a clinical collaboration with Merck, respiratory diseases such as COVID-19 and asthma, gastrointestinal diseases, and pre-clinical programs targeting neurological diseases like Parkinsons disease and auto-immune diseases. It is also engaging in a vaccine research collaborative alliance with Merck.

Peyton said that despite the operational and economic challenges in 2020 created by the global pandemic, the biotech has made significant strides on several fronts.

This includes 4D Pharma presenting clinical data for live biotherapeutics for the treatment of cancer in combination with Mercks Keytruda, as well as positive Phase II results for the first drug candidate able to treat both IBS-C and IBS-D. In addition, earlier in 2020, 4D Pharma was able to quickly instigate a Phase II clinical trial in COVID-19 based on our detailed understanding of our asthma program.

What are the big next steps, and what is the regulatory approval timeline looking like for 4D Pharmas live biotherapeutics?

That really depends on the pathway we take, in the coming weeks and months, in relation to our oncology program, in particular.

We want to expand on the data we have seen recently in relation to oncology and IBS and take that through to approval trials.

The IBS trial will probably take longer, as there is need to address a large patient population. The oncology space is slightly different, and there is [an option] to get an accelerated approval.

Product registration is within reach then. I would say we are just a couple of years, not a decade, away from approval.

4D Pharma is a leader in the field, he said. From a research point of view, we are streets ahead.

The company understands the mechanisms of action of its strains and can demonstrate that preclinically and in patients, he said.

Those capabilities are supported by nearly 1,000 granted patents. I think we have a similar number of patents in development, and all of our IP is generated in-house, our team is pushing forward mechanistic understanding.

And Mercks engagement is a validation of 4Ds clinical pipeline and research capabilities, he added.

The companys platform, he said, goes beyond just addressing diseases of the gut, to explore oncology and immune system related areas. We are also starting to understand and unpick how our bacteria actually act on the gut-brain axis, continued Peyton.

Such insights could potentially lead to innovation in the neurodegenerative disease field, he said.

And the CEO sees Big Pharma's attitudes to the live biotherapeutics field changing.

We have been working with Merck, who I believe to be one of the most innovative of Big Pharma companies, for the past two and half years. We have been working with them on Keytruda, which is probably the biggest selling drug in the world right now, we are looking at how we can expand the patient groups into which Keytruda is active or regenerate a response for the drug, as it does not work in all patients. That is a signal of Mercks belief in the microbiome.

On top of that, Merck asked us to explore what we could do for it in relation to its vaccine business. We have that vaccine program [set up] now, we are doing all the research, and Merck will take it on from the preclinical stage.

As we publish more data on oncology and IBS, we are getting more incoming calls.

The landscape continues to change, some Big Pharma companies want to wait and see, others want to get involved and Merck is one of those.

4D Pharma has six clinical programs, namely a Phase I/II study of MRx0518 in combination with Keytruda (pembrolizumab) in solid tumors, a Phase I study of MRx0518 in a neoadjuvant setting for patients with solid tumors, a Phase I study of MRx0518 in patients with pancreatic cancer, a Phase I/II study of MRx-4DP0004 in asthma, a Phase II study of MRx-4DP0004 in patients hospitalized with COVID-19, and Blautix (R) in Irritable Bowel Syndrome (IBS) which has completed a successful Phase II trial.

Preclinical stage program include candidates for CNS disease such as Parkinson's disease and other neurodegenerative conditions.

Read the original here:
US listing set to support and accelerate ongoing development of 4D Pharma's live biotherapeutics -

Recommendation and review posted by Alexandra Lee Anderson

What’s Wrong With Health Care in the United States? – Psychiatric Times

Health care in the United States is in poor health, its quality steadily declining since the 1960s. According to the World Economic Forum , in the 1950s the United States ranked first among the developed nations in the quality of health care. But now, despite enlisting renowned physicians, public health experts, economists, business leaders, and specialists in the treatment of ailing systems, we rank near the bottom.

What is the explanation? Is something being overlooked in the current effort to improve medical care? Do we not understand the cause of this fatal condition? The authors believe it is the importance of relationships that is being ignored; the physician-patient relationship, family relationships, and relationship systems in the community. Four key elements in our current health care system are responsible for this failure to acknowledge these critical relationships.

Interchangeability of parts

The foundation of the Industrial Revolution was the ability to create interchangeable parts. For example, workers on an assembly line build excellent automobiles cost-effectively. Health care administrators are using that model in medicine. The model of industrialized medicine works poorly when dealing with human beings, and is cost-effective only in the short run. Patients and practitioners are not interchangeable parts. Patients and their illnesses are too complex for a one-size-fits-all design. A health care model that does not recognize each patient as a unique person existing in a unique network of relationshipswith medical practitioners, family, and communityresults in increasingly poor outcomes, as the data demonstrate.

Systematic ignoring of the physician-patient and physician-family relationships

Treatment outcomes decline when patients see a different physician at each visit. The industrialized model excludes the importance of relatedness between physician and patient, losing the stabilizing relational linkages. For example, patients in hospitals cared for by their primary care physician are more likely to be discharged home and less likely to die within 30 days than those cared for by hospitalists who do not have an ongoing relationship with the patient and family.

The lack of sustained relationships between physicians and patients, and physicians and families, in the context of their community, impairs the effectiveness of treatment. It is costly to the physicians sense that their work is meaningful, and thus costly to physician morale. Systems that fail to attend to the physician-patient relationship lead to decreased treatment effectiveness, physician burnout, early retirement, and increased rates of physician suicide.

Healing is more likely in the context of families than healing in isolation

Without attention to context, our words, actions, and experience have no meaning. Family and community relationships are the context of our patients lives. Strong social connections are associated with increased longevity. For example, marriage is a protective factor against cardiac disease and the death of a spouse is associated with increased rates of physical illness in the surviving spouse. For individuals with a chronic illness, treatment without consideration of family and community appears simpler and more efficient, but leads to sterile, out-of-context, uninformed treatment, blinding both the patient and the physician from seeing both the illness and the solution.

The undermining and erosion of family and community

Regulations and reimbursement systems that reduce the medical interaction to a specific procedure diminish the involvement of families and communities in a patients recovery. The Health Information Portability and Accountability Act (HIPAA), for example, which was established to protect patient confidentiality, immediately became an obstacle to communication with the people in the patients life who can help with follow-up appointments, medication adherence, continuity of care, and emotional support.

Treating the correct condition

The 4 elements described point to both the fatal condition and its solution. Attention to the whole person, focusing on relationships with physicians and nurses, patients and families, and the web of community relationships available in every community to every patient, helps people get and stay healthy. Any potential solution to the health care system that ignores relationships will always be ineffective. If industrial medicine worked, and at this point weve done that experiment, costs would not be rising, patients and physicians would not be dissatisfied, and health would be improving.

Dr Copansis Adjunct Associate Professor, Geisel School of Medicine at Dartmouth, Hanover, NH.Dr Rahmaniis training director of Child and Adolescent Psychiatry at the University of Florida.

*Members of the Research Committee, Group for the Advancement of Psychiatry also include Dr John Beahrs, Emeritus Professor of Psychiatry, Oregon Health and Science University, Portland; Dr Allan Josephson, (Former) Professor and Chief, Division of Child and Adolescent Psychiatry, University of Louisville School of Medicine; Dr David Keith, Professor Emeritus, Department of Psychiatry and Behavioral Sciences, Upstate Medical Center, Syracuse, NY; Dr Patrick Malone (19442016); Dr Alan Swann, Professor of Psychiatry, Baylor College of Medicine, and staff psychiatrist, Houston VA Medical Center; Dr William Swift, Emeritus Clinical Professor of Psychiatry, University of Wisconsin School of Medicine and Public Health, Madison; Dr Johan Verhulst (19382019); and Dr Douglas Kramer, Emeritus Clinical Professor of Psychiatry, University of Wisconsin School of Medicine and Public Health, Madison, and Chair, GAP Research Committee.

Continue reading here:
What's Wrong With Health Care in the United States? - Psychiatric Times

Recommendation and review posted by Alexandra Lee Anderson

4D Pharma to host virtual KOL event reviewing new data presented at the Society for Immunotherapy of Cancer annual meeting 2020 from Live Biotherapeut…

4D Pharma to host virtual KOL event reviewing new data presented at the Society for Immunotherapy of Cancer annual meeting 2020 from Live Biotherapeutic MRx0518 clinical programs

Leeds, UK, November 5, 2020, 4D pharma plc(AIM: DDDD), a pharmaceutical company leading the development of Live Biotherapeutic products (LBPs) - a novel class of drug derived from the microbiome, today announces that it will host a virtual Key Opinion Leader (KOL) event to review data presented from two ongoing clinical trials of MRx0518, the Companys lead immuno-oncology single strain Live Biotherapeutic, as both a neoadjuvant monotherapy and combination therapy in patients refractory to checkpoint inhibitors at the Society for Immunotherapy of Cancer (SITC) Annual Meeting 2020. The event will take place on Wednesday, November 11, 2020 at 1:00pm GMT (8:00am ET).

The event will feature presentations from 4D pharma management and KOLs, Dr Mark P Lythgoe, Academic Clinical Fellow in Medical Oncology and Pharmacist at Imperial College London, and Dr Shubham Pant, Associate Professor Department of Investigational Cancer Therapeutics and Department of Gastrointestinal Medical Oncology at the University of Texas MD Anderson Cancer Center.

A live webcast of the event will be available on the Reports and Presentations section of the 4D Pharma website To access the call, please dial 1-877-270-2148 (United States) or 1-412-902-6510 (international) and reference the 4D pharma conference call to join. A replay of the webcast and accompanying slides will be available on the 4D pharma website following the event.

About 4D pharma

Founded in February 2014, 4D pharma is a world leader in the development of Live Biotherapeutics, a novel and emerging class of drugs, defined by the FDA as biological products that contain a live organism, such as a bacterium, that is applicable to the prevention, treatment or cure of a disease. 4D has developed a proprietary platform, MicroRx(R), that rationally identifies Live Biotherapeutics based on a deep understanding of function and mechanism.

4D pharma's Live Biotherapeutic products (LBPs) are orally delivered single strains of bacteria that are naturally found in the healthy human gut.The Company has six clinical programmes, namely a Phase I/II study of MRx0518 in combination with KEYTRUDA (pembrolizumab) in solid tumours, a Phase I study of MRx0518 in a neoadjuvant setting for patients with solid tumours, a Phase I study of MRx0518 in patients with pancreatic cancer, a Phase I/II study of MRx-4DP0004 in asthma, a Phase II study of MRx-4DP0004 in patients hospitalised with COVID-19, and Blautix(R) in Irritable Bowel Syndrome (IBS) which has completed a successful Phase II trial. Preclinical-stage programmes include candidates for CNS disease such as Parkinson's disease and other neurodegenerative conditions. The Company has a research collaboration with MSD, a tradename of Merck & Co., Inc., Kenilworth, NJ, USA, to discover and develop Live Biotherapeutics for vaccines.

In October 2020 4D pharma announced its intention to merge with Longevity Acquisition Corporation (NASDAQ: LOAC), a special purpose acquisition company (SPAC), and seek a NASDAQ listing.The merger is expected to be completed and the NASDAQ listing of 4D pharma American Depositary Shares (ADSs) under the ticker symbol LBPS is currently expected to become effective in early 2021, subject to approval of 4D Shareholders and Longevity Shareholders, and the SEC review process.

For more information, refer to

Here is the original post:
4D Pharma to host virtual KOL event reviewing new data presented at the Society for Immunotherapy of Cancer annual meeting 2020 from Live Biotherapeut...

Recommendation and review posted by Alexandra Lee Anderson

Global Biohacking Market- Industry Analysis and Forecast (2020-2027) By Type, Product, Application, End User, and Region. – Bipartisan Millennial

Global Biohacking Marketwas valued US$ XX Bn in 2019 and is expected to reach US$ XX Bn by 2027, at a CAGR of XX % during a forecast period.

The report study has analyzed the revenue impact of the COVID-19 pandemic on the sales revenue of the market leader, market followers, and market disrupters in the report, and the same is reflected in our analysis.

Biohacking is manipulating the biology of the brain or the body itself to enhance performance. It is known as the first widespread technological step towards human augmentation and improvement.


Global Biohacking Market, Dynamics:

Currently, biohacking takes place outside the established structures of science and medical research. Exploring innovative trends of neuro-nutrition and biohacking in the wellness space is expected to drive the global Biohacking market. An increase in the use of radiofrequency identification (RFID) technology in medical devices, penetration of internet of things (IoT) in healthcare, fitness, and consumer electronics are some of the prominent drivers behind the growth of the global Biohacking market. The requirement for quality healthcare needs among the populace, rise in awareness of biohacking, the prevalence of chronic diseases, and demand for smart devices and drugs are expected to boost the market growth during the forecast period.

On the other hand, stringent regulations, lack of funds required for research, and expertise are expected to limit the global biohacking market during the forecast period.

Global Biohacking Market, Segment Analysis:

Biohacking claims that enhancing and optimizing human performance, which leads to longevity. Biohackers focus on longevity through everything they do to upgrade their life and lifestyle.

Smart drugs are expected to contribute a XX% share in the global biohacking market. Nootropics are cognitive enhancers, which are available in the natural or synthetic form of substances. It helps to enhance mental skills and divided into three general categories: Dietary supplements, synthetic compounds, and prescription drugs. Supplements for memory boosting are commonly taken by students during exam periods. Consumers are seeking to optimize cognitive function and follow a nutrient-dense diet to manage their stress and work on enhancing their sleep quality. The smart drugs are supplement that complements the healthcare concern related to the human being.Forensic Laboratories are expected to contribute a XX% share in the global biohacking market. The scientists and research individuals are conducted various laboratory experiments to explore new avenues in biotechnology, genetic engineering, and molecular biology. The Biohackers embark on various experiments on the body like monitoring of the heart rate or insertion of microchips to control the stress level. They have developed various products to explore the human body. Some of the remarkable products include smart drugs, microchips, magnetic fingertips, brain sensors, RFID implants, body sensors, and smart blood pressure monitor health trackers.

Currently, wearable analytic technological devices are widely available in the market. The current generation has a positive approach towards the biohacking and its devices. The tracking of the heart rate, steps, blood sugar level, and movement of the body can be analyzed through the biohacking analytics.

Global Biohacking Market, Regional Analysis:

North America region held the dominant position in 2019 and it is projected to continue its dominance in the biohacking market during the forecast period. Dominance is attributed to the presence of the strategic presence of key players in the developed countries like the US and Canada. The region has the potential to surpass a market valuation of US $ XX Mn by 2019 and is projected to maintain its top position in the global market. Besides, an introduction of the biotechnologies and existence of the synthetic biology key players are expected to boost the market growth.

The objective of the report is to present a comprehensive analysis of the Global Biohacking Market including all the stakeholders of the industry. The past and current status of the industry with forecasted market size and trends are presented in the report with the analysis of complicated data in simple language. The report covers all the aspects of the industry with a dedicated study of key players that includes market leaders, followers, and new entrants by region. PORTER, SVOR, PESTEL analysis with the potential impact of micro-economic factors by region on the market has been presented in the report. External as well as internal factors that are supposed to affect the business positively or negatively have been analyzed, which will give a clear futuristic view of the industry to the decision-makers.The report also helps in understanding Global Biohacking Market dynamics, structure by analyzing the market segments and projects the Global Biohacking Market size. Clear representation of competitive analysis of key players by Application, price, financial position, Product portfolio, growth strategies, and regional presence in the Global Biohacking Market make the report investors guide.


Scope of the Global Biohacking Market

Global Biohacking Market, By Type

Outside Biohacking Inside BiohackingGlobal Biohacking Market, By Product

Smart Drugs Sensors Strains OthersGlobal Biohacking Market, By Application

Synthetic Biology Genetic Engineering Forensic Science Diagnosis & Treatment Drug Testing OthersGlobal Biohacking Market, By End User

Pharmaceutical & Biotechnology Companies Forensic Laboratories OthersGlobal Biohacking Market, By Region

North America Europe Asia Pacific Middle East & Africa South AmericaKey players operating in Global Biohacking Market

Fitbit, Inc. Apple Synbiota The Odin HVMN, Inc. Thync Global Inc., U.S.A MoodMetric InteraXon Inc. Behavioral Tech

Browse Full Report with Facts and Figures of Biohacking Market Report at:

About Us:

Maximize Market Research provides B2B and B2C market research on 20,000 high growth emerging technologies & opportunities in Chemical, Healthcare, Pharmaceuticals, Electronics & Communications, Internet of Things, Food and Beverages, Aerospace and Defense and other manufacturing sectors.

Contact info:

Name: Vikas Godage



Contact: +919607065656/ +919607195908

View post:
Global Biohacking Market- Industry Analysis and Forecast (2020-2027) By Type, Product, Application, End User, and Region. - Bipartisan Millennial

Recommendation and review posted by Alexandra Lee Anderson

Page 21234..1020..»